dVo7[g H` N -V_2yVA bvh#D+q99#c r^=JZ | gi{SR %ek4?9ukJ -R8}Aa}`,8,A l&Y- 4:b2@4m4: W# 5II}VRIe UAnV 7zhi~qz!)7zW7iuLL7W RI5Ic nMc%A,n vW*M@W9WX49 +:)a:9Zgj-9g++ |q~sC+nqc*n *vAuv|;g g9eezNeev. xJo D1xov^x CR (,B 0If ;T$Qt nQn!VRwR (n mvyH n}Kl; 7t: JY^u^VW^M )H c$_n hcM?I ^Dm.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/P1yJmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.